Malignant Pleural Mesothelioma - Pipeline Insight, 2024

This “Malignant Pleural Mesothelioma- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant pleural mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant Pleural Mesothelioma Understanding

Malignant Pleural Mesothelioma: Overview

Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleural surface. It is associated with previous asbestos exposure, with a latency period of ~40 years between fibre exposure and disease presentation. Global incidence of MPM has risen steadily over the past decade, and is predicted to continue to an estimated peak in 2020. Prognosis with MPM is poor and median survival ranges from 8 to 14 months from diagnosis. Women have a more favourable outlook than men, but due to the occupational nature of the disease there is a male predominance of 4:1. There are four main histological sub-types; epithelioid, sarcomatoid, biphasic or mixed, and desmoplastic. The majority of MPM cases are caused by prior exposure to asbestos, often occurring >40 years previously. Other causes of MPM include erionite (a mineral found in the rocks of Turkey), chest wall radiation and simian virus

Malignant Pleural Mesothelioma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Pleural Mesothelioma pipeline landscape is provided which includes the disease overview and Malignant Pleural Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Malignant pleural mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Pleural Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Malignant pleural mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Malignant pleural mesothelioma.

Malignant Pleural Mesothelioma Emerging Drugs Chapters

This segment of the Malignant Pleural Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Pleural Mesothelioma Emerging Drugs

NGR-TNF: MolMed NGR-TNF is a recombinant protein that allows to increase the concentration of immunity cells and chemotherapeutic drugs at the tumour level through the permeabilization of tumour vessels. NGR-LTNF is currently being investigated in Phase 3 stage of development for the treatment of Malignant PleuralMesothelioma.

Pembrolizumab : Merck & Co Pembrolizumab, a programmed cell death 1 (PD-1)-blocking antibody, is being used with increasing frequency for solid tumors positive for the programmed cell death ligand 1 (PD-L1) biomarker. There have been reports of antitumor activity in several malignancies with increased PD-L1 expression, including non-small-cell lung cancer. While recent reports have shown remarkable clinical improvement from salvage immunotherapy in cases of advanced malignant pleural mesothelioma(MPM).

Pegargiminase: Polaris Pharmaceuticals Pegargiminase, a novel targeted cancer therapy that depletes circulating arginine in combination with standard chemotherapies and immuno-oncology drugs in various cancers, including hepatocellular carcinoma and mesothelioma. Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma (HCC) and malignant pleural mesothelioma (MPM). Pegargiminase is well tolerated, both as a monotherapy and as part of a combination therapy.

Lurbinectedin: Pharma Mar Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds. Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks andapoptosis.

YS110: Ys Therapeutics YS110 is a recombinant humanized monoclonal antibody that binds with high affinity (dissociation constant, 0.244 nM) to human CD26. Extensive in vitro and in vivo studies have shown that YS110 possesses antitumor activity for malignant mesothelioma cell lines. Single or repeated intravenous administration of YS110 has also been found to be safe in nonhuman primates.YS110 is currently being investigated in Phase1/2 for the treatment of Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma: Therapeutic Assessment

This segment of the report provides insights about the different Malignant Pleural Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Malignant Pleural Mesothelioma

There are approx. 20+ key companies which are developing the therapies for Malignant pleural mesothelioma. The companies which have their Malignant pleural mesothelioma drug candidates in the most advanced stage, i.e. phase III include, MolMed.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Malignant pleural mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Pleural Mesothelioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Pleural Mesothelioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Mesothelioma drugs.

Malignant Pleural Mesothelioma Report Insights

• Malignant Pleural Mesothelioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant Pleural Mesothelioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant pleural mesothelioma drugs?
• How many Malignant pleural mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant pleural mesothelioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant pleural mesothelioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant pleural mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MolMed
• Pharma Mar
• Ys Therapeutics
• Merck Sharp & Dohme Corp.
• Kissei Pharmaceutical Co., Ltd.
• Novo CureLtd
• AGC Biologics S.p.A
• Aduro Biotech, Inc
• Novartis
• Bristol-Myers Squibb
• Novartis
• TCR2 Therapeutics
• Novotech (Australia) Pty Limited
• AstraZeneca
• Hoffmann-La Roche
• Polaris Pharmaceuticals
• Kyorin Pharmaceuticals
• ACADIA Pharmaceuticals

Key Products

• Pegargiminase
• Pembrolizumab
• YS110
• Lurbinectedin
• NGR-LTNF
• MTG201
• Atezolizumab
• Bevacizumab
• Imfinzi
• TR002

This product will be delivered within 1-3 business days.